Greater Glasgow and Clyde Medicines

GGC Medicines App & Adult Therapeutics Handbook (Desktop version) Upgrade The GGC Medicines App and desktop site software is being upgraded in June and July for launch in August 2016. Users will notice the following...

NHSGGC Guidelines now available on StaffNet Updated guidelines - The following guidelines have been updated and reposted on StaffNet.  Some updates may involve significant clinical changes and ...

This post summarises the latest NHS Greater Glasgow and Clyde decisions relating to new medicines considered by the Area Drug and Therapeutics Committee (ADTC).  The new format, which is aimed at the public and patients is currently being piloted.

For full details of the medicines included in this post that are available for use, please see the relevant entry in the GGC Formulary.

Since August 2015 the content of the Therapeutics Handbook has only been available online via the GGC Medicines website and the App.  This allows greater flexibility to update guidelines during the year rather than at one point in time for...

This post summarises the latest NHS Greater Glasgow and Clyde decisions relating to new medicines considered by the Area Drug and Therapeutics Committee (ADTC).  The new format, which is aimed at the public and patients is currently being piloted.

For full details of the medicines included in this post that are available for use, please see the relevant entry in the GGC Formulary.

Apixaban: DOAC of choice for Deep Vein Thrombosis (DVT)/Pulmonary Embolism (PE)NHSGGC guidance recommends either a DOAC (Direct Oral Anti...

New and updated NHSGGC Guidelines now available on StaffNet

Prescribing in Myasthenia Gravis Key messages • Delay or omission of Myasthenia Gravis (MG) medicines can very quickly result in a significant worsening of the patient’s myasthen...

  Oral Proton Pump Inhibitors

• Proton Pump Inhibitors (PPIs) are one of the most commonly prescribed classes of drug
• PPIs are an effective treatment when used appropriately
• PPIs should only be prescribed where there is a clear indication
• PPIs are usually well tolerated
• Recent evidence suggests that PPIs may have potentially serious adverse effects such as fractures, hypomagnesaemia, subacute cutaneous lupus erythematosus, pneumonia and Clostridium difficile infection

Greater Glasgow and Clyde Area Drug and Therapeutics Committee met on Monday 14th December. This blog details the Formulary decisions made at that meeting.